Clinical Trials Browser

Phase 3 × Breast Neoplasms × 130-nm albumin-bound paclitaxel × Clear all

NCT07060807 2026-03-16

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Phase 3 Recruiting

Breast Neoplasms

NCT06312176 2026-03-13

MK-2870-010

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT04895358 2026-03-11

KEYNOTE-B49

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis

NCT06018337 2026-03-05

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

Phase 3 Active not recruiting

Breast Neoplasms

NCT04494425 2026-03-04

DB-06

Phase 3 Active not recruiting

866 enrolled 25 charts 1 FDA

Breast Neoplasms

NCT05374512 2026-01-27

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Phase 3 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT07071337 2025-12-11

A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy

Phase 3 Recruiting

Breast Neoplasms

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Phase 3 Active not recruiting

557 enrolled 22 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT05840211 2025-10-03

ASCENT-07

Phase 3 Active not recruiting

Breast Neoplasms

NCT02514681 2025-09-10

PRECIOUS

Phase 3 Completed

Breast Neoplasms

NCT02344472 2024-06-04

Detect V / CHEVENDO (Chemo vs. Endo)

Phase 3 Active not recruiting

Breast Neoplasms

NCT01822314 2024-03-07

ETNA

Phase 3 Completed

Breast Neoplasms, Neoplasms

NCT04335006 2023-05-06

A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Phase 3 Terminated

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02915744 2023-04-14

ATTAIN

Phase 3 Completed

178 enrolled 37 charts

Breast Neoplasms, Carcinoma, Neoplasm Metastasis

NCT00785291 2022-10-10

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

Phase 3 Completed

799 enrolled 18 charts

Breast Neoplasms

NCT01690702 2021-02-02

GAIN-2

Phase 3 Completed

Breast Neoplasms

NCT01572038 2020-09-25

PERUSE

Phase 3 Completed

1,436 enrolled 53 charts

Breast Neoplasms

NCT02019277 2018-09-13

SAPPHIRE

Phase 3 Completed

50 enrolled 18 charts

Breast Neoplasms